Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285185611> ?p ?o ?g. }
- W4285185611 endingPage "204062072210910" @default.
- W4285185611 startingPage "204062072210910" @default.
- W4285185611 abstract "Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, chronic hematologic disorder associated with inappropriate terminal complement activity on blood cells that can result in intravascular hemolysis (IVH), thromboembolic events (TEs), and organ damage. Untreated individuals with PNH have an increased risk of morbidity and mortality. Patients with PNH experiencing IVH often present with an elevated lactate dehydrogenase (LDH; ⩾ 1.5 × the upper limit of normal) level which is associated with a significantly higher risk of TEs, one of the leading causes of death in PNH. LDH is therefore used as a biomarker for IVH in PNH. The main objective of PNH treatment should therefore be prevention of morbidity and mortality due to terminal complement activation, with the aim of improving patient outcomes. Approval of the first terminal complement inhibitor, eculizumab, greatly changed the treatment landscape of PNH by giving patients an effective therapy and demonstrated the critical role of terminal complement and the possibility of modulating it therapeutically. The current mainstays of treatment for PNH are the terminal complement component 5 (C5) inhibitors, eculizumab and ravulizumab, which have shown efficacy in controlling terminal complement-mediated IVH, reducing TEs and organ damage, and improving health-related quality of life in patients with PNH since their approval by the United States Food and Drug Administration in 2007 and 2018, respectively. Moreover, the use of eculizumab has been shown to reduce mortality due to PNH. More recently, interest has arisen in developing additional complement inhibitors with different modes of administration and therapeutics targeting other components of the complement cascade. This review focuses on the pathophysiology of clinical complications in PNH and explores why sustained inhibition of terminal complement activity through the use of complement inhibitors is essential for the management of patients with this chronic and debilitating disease." @default.
- W4285185611 created "2022-07-14" @default.
- W4285185611 creator A5045018770 @default.
- W4285185611 creator A5067262609 @default.
- W4285185611 creator A5068469918 @default.
- W4285185611 creator A5083424368 @default.
- W4285185611 creator A5089636175 @default.
- W4285185611 date "2022-01-01" @default.
- W4285185611 modified "2023-10-09" @default.
- W4285185611 title "The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria" @default.
- W4285185611 cites W1571752123 @default.
- W4285185611 cites W1717575538 @default.
- W4285185611 cites W1935314190 @default.
- W4285185611 cites W1978700432 @default.
- W4285185611 cites W1985084429 @default.
- W4285185611 cites W1989190382 @default.
- W4285185611 cites W1990806139 @default.
- W4285185611 cites W1995181352 @default.
- W4285185611 cites W1999997207 @default.
- W4285185611 cites W2015258163 @default.
- W4285185611 cites W2023377972 @default.
- W4285185611 cites W2029549314 @default.
- W4285185611 cites W2032628053 @default.
- W4285185611 cites W2033993025 @default.
- W4285185611 cites W2050915105 @default.
- W4285185611 cites W2058082996 @default.
- W4285185611 cites W2065405494 @default.
- W4285185611 cites W2078957722 @default.
- W4285185611 cites W2094698810 @default.
- W4285185611 cites W2112430000 @default.
- W4285185611 cites W2121920823 @default.
- W4285185611 cites W2127290864 @default.
- W4285185611 cites W2130696459 @default.
- W4285185611 cites W2135639179 @default.
- W4285185611 cites W2150027863 @default.
- W4285185611 cites W2151709211 @default.
- W4285185611 cites W2152757679 @default.
- W4285185611 cites W2163541746 @default.
- W4285185611 cites W2171068466 @default.
- W4285185611 cites W2267134012 @default.
- W4285185611 cites W2335653426 @default.
- W4285185611 cites W2340165058 @default.
- W4285185611 cites W2427944740 @default.
- W4285185611 cites W2471377830 @default.
- W4285185611 cites W2516076895 @default.
- W4285185611 cites W2553113616 @default.
- W4285185611 cites W2562625144 @default.
- W4285185611 cites W2606230253 @default.
- W4285185611 cites W2616618502 @default.
- W4285185611 cites W2705109811 @default.
- W4285185611 cites W2737109721 @default.
- W4285185611 cites W2789800668 @default.
- W4285185611 cites W2791213254 @default.
- W4285185611 cites W2794135056 @default.
- W4285185611 cites W2889134887 @default.
- W4285185611 cites W2899354403 @default.
- W4285185611 cites W2899663130 @default.
- W4285185611 cites W2901614266 @default.
- W4285185611 cites W2902552969 @default.
- W4285185611 cites W2903198260 @default.
- W4285185611 cites W2909588901 @default.
- W4285185611 cites W2914314726 @default.
- W4285185611 cites W2914587352 @default.
- W4285185611 cites W2951566892 @default.
- W4285185611 cites W2972902078 @default.
- W4285185611 cites W2978527832 @default.
- W4285185611 cites W2981492072 @default.
- W4285185611 cites W2986030647 @default.
- W4285185611 cites W2988291220 @default.
- W4285185611 cites W2999361795 @default.
- W4285185611 cites W3001593205 @default.
- W4285185611 cites W3011562564 @default.
- W4285185611 cites W3014562531 @default.
- W4285185611 cites W3022268070 @default.
- W4285185611 cites W3083036202 @default.
- W4285185611 cites W3092190815 @default.
- W4285185611 cites W3094032026 @default.
- W4285185611 cites W3094234317 @default.
- W4285185611 cites W3094895075 @default.
- W4285185611 cites W3111386845 @default.
- W4285185611 cites W3111780294 @default.
- W4285185611 cites W3114620383 @default.
- W4285185611 cites W3136167138 @default.
- W4285185611 cites W3139722173 @default.
- W4285185611 cites W3159299798 @default.
- W4285185611 cites W3164044269 @default.
- W4285185611 cites W3185980667 @default.
- W4285185611 cites W3192261022 @default.
- W4285185611 cites W3196114252 @default.
- W4285185611 cites W3213196162 @default.
- W4285185611 cites W4200193990 @default.
- W4285185611 cites W4249789249 @default.
- W4285185611 cites W4292399048 @default.
- W4285185611 doi "https://doi.org/10.1177/20406207221091046" @default.
- W4285185611 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35663504" @default.
- W4285185611 hasPublicationYear "2022" @default.
- W4285185611 type Work @default.
- W4285185611 citedByCount "6" @default.